David Brian Karpf,Ken nett Sprogøe,Lars Holten-Andersen
申请号：
US16337803
公开号：
US20190224329A1
申请日:
2017.09.28
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preventing a condition which can be treated, controlled, delayed or prevented with PTH, wherein the pharmaceutical composition comprising the controlled-release PTH compound is administered in accordance with a dosage regimen in which dose adjustment in response to hypocalcemia or hypercalcemia is performed in increments of no more than 25%.
